A federal jury in Dallas ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
Manufacturers and their communications agencies see great opportunities in a new draft guidance from FDA, but the fear of warning letters still shadows the industry.
Market pressures have continued to threaten pharmaceutical brand revenue while increasing costs. The convergence of these two forces has challenged pharmaceutical manufacturers to improve margin with new and ever-evolving strategies. Only a combination of sophisticated managed markets expertise and real-world analysis can empower brands to maximize profitability in today’s challenging climate.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
The HBA’s 28th annual Woman of the Year luncheon was held on May 11th at the New York Hilton Midtown.
Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai
Despite the general anxiety over the impact of President Trump’s policies, when it comes to pharmaceutical sales forces, little of what he does will actually affect pharma sales-force strategies. The trends that are continuing to play out are declining rep access, the size of pharma sales forces, and the struggle with the concept of key account management, as well as trying to figure out how reps should be compensated.
U.S. trends in aggregate spend, disclosure, and transparency: Writing the next chapter on transparency initiatives
QuintilesIMS’ annual survey of pharmaceutical and device manufacturers was initiated in 2009 – when only a handful of U.S. states required disclosure of certain healthcare practitioner payments. Since then, of course, state, federal and global requirements have continually evolved and expanded. Our latest survey findings, which reflect responses from 112 manufacturers, underscore that while the bar keeps getting higher, manufacturers’ confidence and sophistication are also on the rise.
“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).
The live video, real-time communications company (RTC) TokBox announced the results of its inaugural “Live Video Maturity Study.”
Acorda Therapeutics Inc. said five people died in clinical trials for the company’s Parkinson’s disease drug, the latest in a series of setbacks for the drugmaker.
Mylan reportedly let go between 200 and 300 people from its West Virginia operations.
Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.
Shares of Zymeworks shot up more than 33 percent after the company announced a licensing deal with Janssen Biotech to develop six bispecific antibodies.
W2O Group, a network of innovative analytics-driven, digital-first marketing and communications firms, announced the appointment of three senior executives in its growing Chicago office.
Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.
GlaxoSmithKline poached veteran drug industry scientist Hal Barron from Alphabet-funded Calico to be its research head.
Regeneron Pharmaceuticals reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for its flagship eye treatment Eylea and new eczema drug Dupixent.
Shares of Mallinckrodt Plc were down after the drugmaker reported lower-than-expected quarterly revenue.
Roche company Genentech indicated it is laying off 130 people at its facility in Vacaville, Calif. by the end of 2017. Amgen is reportedly eliminating about 200 R&D jobs, mostly in California, by the end of 2017.
Osiris Therapeutics settled a case of accounting fraud with the U.S. SEC, but four former company executives will face charges for the alleged financial misreporting.
The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in third-quarter 2017.
Precision Value & Health announced the formation of Precision Xtract – a new, focused alignment of the company’s global market access consulting services.
Drugmaker Novo Nordisk warned that draft legislation in some U.S. states to make pricing more transparent could impact business in the company’s largest market.
Pfizer Inc.’s third-quarter profit beat market estimates and the company raised its full-year 2017 earnings forecast.
Publicis Health announced the integration of Publicis LifeBrands Medicus (PLBM) into Saatchi & Saatchi Wellness (SSW) to create a new Wellness Intelligence-driven agency designed to help health and wellness-oriented audiences navigate the expanding “Wellness Culture.”
AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.
U.S. pharmacy operator CVS Health Corp. made an offer to acquire No. 3 U.S. health insurer Aetna Inc. for more than $200 per share, or over $66 billion, sources said.